

- 1 1. (Currently Amended) A pharmaceutical composition comprising:
 - 2 a) from about 0.1% to about 50 % by weight of lamotrigine or acid
3 addition salt thereof;
 - 4 b) from about 15.5% to about 70% by weight of microcrystalline
5 cellulose;
 - 6 c) from about 0.1% to about 14.5% by weight of sodium starch glycolate;
7 and
 - 8 d) from about 0.1% to about 4.5% by weight of polyvinylpyrrolidone.
- 1 2. (Original) The pharmaceutical composition according to claim 1, further comprising from
2 about 0.1% to about 14.5% by weight of lactose.
- 1 3. (Cancelled).
- 1 4. (Cancelled).
- 1 5. (Original) The pharmaceutical composition according to claim 2, wherein the
2 composition comprises about 20% to about 70% by weight of microcrystalline cellulose,
3 about 0.1% to about 10% by weight of sodium starch glycolate, about 0.1% to about 3% by
4 weight of polyvinylpyrrolidone, and about 0.1% to about 10% by weight of lactose.
- 1 6. (Original) The pharmaceutical composition according to claim 1, wherein the sodium
2 starch glycolate is intragranular.
- 1 7. (Original) The pharmaceutical composition according to claim 1, wherein the sodium
2 starch glycolate is extragranular.
- 1 8. (Original) The pharmaceutical composition according to claim 1, wherein the
2 composition is a tablet.
- 1 9. (Original) The pharmaceutical composition according to claim 1, wherein at least 80% by
2 weight of the lamotrigine or the acid addition salt thereof dissolves within 10 minutes.
- 1 10. (Original) The pharmaceutical composition according to claim 1, wherein at least 90% by
2 weight of the lamotrigine or the acid addition salt thereof dissolves within 30 minutes.

1 11. (Original) The pharmaceutical composition according to claim 1, wherein the
2 composition is stable after three months storage at 40°C and 75% RH with at least 98% of the
3 lamotrigine or acid addition salt thereof remaining after three months.

1 12. (Original) A process for preparing a pharmaceutical composition, the process comprising
2 wet granulating a composition that includes:

- 3 a) from about 0.1% to about 50 % by weight of lamotrigine or acid addition salt
4 thereof;
- 5 b) from about 15.5% to about 70% by weight of microcrystalline cellulose;
- 6 c) from about 0.1% to about 14.5% by weight of sodium starch glycolate; and
- 7 d) from about 0.1% to about 4.5% by weight of polyvinylpyrrolidone.

1 13. (Original) The process according to claim 12, wherein the pharmaceutical composition
2 further comprises from about 0.1% to about 14.5% by weight of lactose.

1 14. (Cancelled).

1 15. (Cancelled).

1 16. (Original) The process according to claim 13, wherein the composition comprises about
2 20% to about 70% by weight of microcrystalline cellulose, about 0.1% to about 10% by
3 weight of sodium starch glycolate, about 0.1% to about 3% by weight of
4 polyvinylpyrrolidone, and about 0.1% to about 10% by weight of lactose.

1 17. (Cancelled).

1 18. (Currently Amended) The process according to claim 12 ~~or 13~~, wherein the
2 lamotrigine or its acid addition salt, microcrystalline cellulose, and sodium starch glycolate,
3 and polyvinylpyrrolidone ~~and/or lactose~~ are blended and then granulated with water.

1 19. (Currently Amended) The process according to claim 12 ~~or 13~~, wherein the lamotrigine or
2 its acid addition salt, microcrystalline cellulose, and sodium starch glycolate ~~and/or lactose~~
3 are blended and then granulated with an aqueous solution of polyvinylpyrrolidone.

1 20. (Currently Amended) The process according to claim 12 ~~18~~, further comprising
2 screening the wet mass to obtain granules.

- 1 21. (Cancelled).
- 1 22. (Original) The process according to claim 20, further comprising drying and sieving the
2 granules.
- 1 23. (Cancelled).
- 1 24. (Original) The process according to claim 22, further comprising compressing the
2 granules to form tablets.
- 1 25. (Cancelled).
- 1 26. (Currently Amended) The process according to claim 12, wherein the sodium starch
2 glycolate is either or both intragranular or extragranular.
- 1 27. (Cancelled).
- 1 28. (Original) A method of treating a medical condition responsive to lamotrigine, the
2 method comprises administering a pharmaceutical composition of lamotrigine, the
3 composition comprising:
- 4 (a) from about 0.1% to about 50% by weight of lamotrigine or acid
5 addition salt thereof;
- 6 (b) from about 15.5% to about 70% by weight of microcrystalline
7 cellulose;
- 8 (c) from about 0.1% to about 14.5% by weight of sodium starch glycolate;
9 and
- 10 (d) from about 0.1% to about 4.5% by weight of polyvinylpyrrolidone.
- 1 29. (Original) The method according to claim 28, wherein the pharmaceutical
2 composition further comprises from about 0.1% to about 14.5% by weight of lactose.